Celldex Therapeutics Stock Today
| CLDX Stock | USD 23.78 1.02 4.48% |
Performance0 of 100
| Odds Of DistressLess than 42
|
Celldex Therapeutics is trading at 23.78 as of the 17th of January 2025; that is 4.48 percent increase since the beginning of the trading day. The stock's open price was 22.76. Celldex Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of January 2023 and ending today, the 17th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of March 2008 | Category Healthcare | Classification Health Care |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey. The company has 66.34 M outstanding shares of which 8.09 M shares are currently shorted by private and institutional investors with about 8.96 trading days to cover. More on Celldex Therapeutics
Moving together with Celldex Stock
Moving against Celldex Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Celldex Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CFO, Senior Vice President | Sam Martin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCelldex Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Celldex Therapeutics' financial leverage. It provides some insight into what part of Celldex Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celldex Therapeutics (CLDX) is traded on NASDAQ Exchange in USA. It is located in Perryville III Building, Hampton, NJ, United States, 08827 and employs 160 people. Celldex Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.51 B. Celldex Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 66.34 M outstanding shares of which 8.09 M shares are currently shorted by private and institutional investors with about 8.96 trading days to cover.
Celldex Therapeutics currently holds about 356.82 M in cash with (107.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63.
Check Celldex Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Celldex Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Celldex Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Celldex Therapeutics. Please pay attention to any change in the institutional holdings of Celldex Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Celldex Ownership Details
Celldex Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-09-30 | 1.8 M | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.7 M | |
| Commodore Capital Lp | 2024-09-30 | 1.6 M | |
| Point72 Asset Management, L.p. | 2024-09-30 | 1.6 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.5 M | |
| Jennison Associates Llc | 2024-09-30 | 1.3 M | |
| Pictet Asset Manangement Sa | 2024-09-30 | 1.1 M | |
| Rock Springs Capital Management Lp | 2024-09-30 | 1.1 M | |
| Novo A/s | 2024-09-30 | 963.7 K | |
| Wellington Management Company Llp | 2024-09-30 | 9.2 M | |
| Fmr Inc | 2024-09-30 | 6 M |
Celldex Therapeutics Historical Income Statement
Celldex Stock Against Markets
Celldex Therapeutics Corporate Management
| Ronald Pepin | Chief Bus. Officer and Sr. VP | Profile | |
| Patrick Till | Senior Communications | Profile | |
| Prof Schlessinger | CoFounder Board | Profile | |
| Diane MD | Senior Officer | Profile | |
| Margo MD | Senior Affairs | Profile |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.